Mei Ri Jing Ji Xin Wen·2025-09-03 23:35Group 1 - The actual controller and chairman of Yong'an Pharmaceutical, Chen Yong, has had his detention lifted, allowing him to resume his duties, which enhances investor confidence in the company's future development [1] - FTSE Russell announced the inclusion of BeiGene and WuXi AppTec in the FTSE China A50 Index, reflecting the increasing importance of A-share companies in the global capital market and foreign investment interest in China's innovative drug sector [2] - Otsuka Pharmaceutical's application for the targeted drug, Belimumab injection, for IgA nephropathy has been accepted, potentially filling a market gap in a field with limited treatment options and providing a new growth point for the company [3] Group 2 - Ruizhi Pharmaceutical announced a partnership to establish a fund focused on investing in innovative drugs and medical devices, which will enhance the company's resource reserves and align with current industry trends [4] - Menova's subsidiary has received approval for Mosapride Citrate Tablets in China, which is expected to generate new revenue growth for the company and strengthen its position in the pharmaceutical industry [5]